First Results of Intravenous Levetiracetam Use in Turkey

Abstract

Objective: Status epilepticus is a neurological emergency feature with a risk of high mortality and morbidity which requires immediate intervention. Many of the medications used in standard treatment have systemic side effects. Levetiracetam (LEV) is one of the new antiepileptic agents which are not metabolized through the liver and have minimal drug interaction. Positive outcomes with intravenous (IV) form of LEV on patients with refractory seizures and status have been reported.